듀셴형 근이영양증 치료제 시장 보고서(2026년)

Duchenne muscular dystrophy (DMD) drugs are medications and therapies designed to manage and slow the progression of Duchenne muscular dystrophy, a genetic disorder that leads to muscle weakness and degeneration. These drugs target the underlying genetic mutations, improve muscle function, and enhance quality of life. The primary goal of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in individuals with DMD.

The main types of drugs in the duchenne muscular dystrophy market include exon skipping drugs, corticosteroids, gene therapy, and other treatments. Exon skipping drugs are specialized therapies that enable the body to produce a functional, albeit shorter, version of the dystrophin protein by bypassing defective sections of the dystrophin gene during protein synthesis. These drugs are administered through oral and injectable routes, and they are distributed via several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have influenced the duchenne muscular dystrophy drugs market by increasing the cost of imported gene therapies, exon skipping drugs, and corticosteroids, which has led to higher treatment costs. Hospital pharmacies and specialty drug segments in regions like North America and Europe are particularly affected due to reliance on imported therapies. While tariffs may temporarily limit accessibility and slow market growth, they also promote local manufacturing initiatives and encourage the development of cost-effective domestic therapies, supporting long-term market resilience.

The duchenne muscular dystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy drugs market statistics, including duchenne muscular dystrophy drugs industry global market size, regional shares, competitors with a duchenne muscular dystrophy drugs market share, detailed duchenne muscular dystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy drugs industry. This duchenne muscular dystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy drugs market size has grown rapidly in recent years. It will grow from $3.2 billion in 2025 to $3.64 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to limited treatment options, increasing awareness of dmd, growing pediatric patient population, adoption of corticosteroids, early-stage r&d in gene therapy.

The duchenne muscular dystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in exon skipping drugs, innovations in gene editing technologies, increasing government and regulatory support, rising investment in rare disease therapies, expansion of specialty care and hospital networks. Major trends in the forecast period include rising adoption of exon skipping therapies, increasing use of gene therapy approaches for dmd, growing preference for injectable and targeted drug delivery, expansion of online and hospital pharmacy distribution channels, development of supportive therapies such as myostatin inhibitors and utrophin modulators.

The expansion of personalized medicine is expected to drive the growth of the Duchenne muscular dystrophy (DMD) drugs market in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic makeup, environmental influences, and lifestyle factors to achieve better clinical outcomes. The increasing adoption of personalized medicine is largely driven by advancements in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored therapies. In the context of Duchenne muscular dystrophy, personalized medicine supports the development of targeted treatments aligned with specific genetic mutations, improving drug effectiveness and overall patient care. It also enhances drug development by concentrating on mutation-specific therapies, leading to improved treatment outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a notable rise from 12 approvals in 2022. Therefore, the growth of personalized medicine is contributing to the expansion of the Duchenne muscular dystrophy drugs market.

Major companies operating in the Duchenne muscular dystrophy drugs market are concentrating on the development of innovative treatment options, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance overall patient outcomes. Corticosteroids are steroid-based medications, either naturally produced by the adrenal glands or synthetically manufactured, that help reduce inflammation and regulate immune responses. For instance, in March 2024, Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, an FDA-approved treatment for Duchenne muscular dystrophy in patients aged two years and older. AGAMREE is a corticosteroid that reduces inflammation and stabilizes muscle cell membranes, thereby helping to slow the progression of the disease.

In July 2023, Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company, acquired the exclusive North American license for vamorolone (AGAMREE), a Duchenne muscular dystrophy drug, from Santhera Pharmaceuticals for an undisclosed amount. Through this acquisition, Catalyst Pharmaceuticals aimed to strengthen its Duchenne muscular dystrophy portfolio by offering a safer and more effective treatment option and addressing the growing demand for targeted therapies for DMD patients. Santhera Pharmaceuticals is a Switzerland-based pharmaceutical company focused on developing innovative treatments for Duchenne muscular dystrophy.

Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc, Sanofi S.A, Novartis AG, Italfarmaco S.p.A, Sarepta Therapeutics Inc, PTC Therapeutics Inc, FibroGen Inc, Wave Life Sciences Ltd, Solid Biosciences Inc, NS Pharma, Capricor Therapeutics Inc, Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc, EspeRare Foundation, Cure Rare Disease, Akashi Therapeutics Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Co Ltd, Nippon Shinyaku Co Ltd, Regenxbio Inc, Ultragenyx Pharmaceutical Inc, Dyne Therapeutics Inc, Entrada Therapeutics Inc.

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duchenne muscular dystrophy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses duchenne muscular dystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Exon Skipping Drugs; Corticosteroids; Gene Therapy; Other Drug Types
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Exon Skipping Drugs: Eteplirsen; Golodirsen; Viltolarsen; Casimersen; Other Exon Skipping Therapies
• 2) By Corticosteroids: Prednisone; Deflazacort; Other Corticosteroids
• 3) By Gene Therapy: Micro-dystrophin Gene Therapy; CRISPR/Cas9-Based Gene Editing; Stem Cell-Based Gene Therapy; Other Gene Therapies
• 4) By Other Drug Types: Utrophin Modulators; Anti-Inflammatory Agents; Antisense Oligonucleotides; Myostatin Inhibitors; Other Supportive Therapies
• Companies Mentioned: Pfizer Inc; Sanofi S.A; Novartis AG; Italfarmaco S.p.A; Sarepta Therapeutics Inc; PTC Therapeutics Inc; FibroGen Inc; Wave Life Sciences Ltd; Solid Biosciences Inc; NS Pharma; Capricor Therapeutics Inc; Santhera Pharmaceuticals; ReveraGen BioPharma; Antisense Therapeutics Limited; Catalyst Pharmaceuticals Inc; EspeRare Foundation; Cure Rare Disease; Akashi Therapeutics Inc; BioMarin Pharmaceutical Inc; Daiichi Sankyo Co Ltd; Nippon Shinyaku Co Ltd; Regenxbio Inc; Ultragenyx Pharmaceutical Inc; Dyne Therapeutics Inc; Entrada Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Duchenne Muscular Dystrophy Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Duchenne Muscular Dystrophy Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Duchenne Muscular Dystrophy Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Duchenne Muscular Dystrophy Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Biotechnology, Genomics & Precision Medicine
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Exon Skipping Therapies
  • 4.2.2 Increasing Use Of Gene Therapy Approaches For Dmd
  • 4.2.3 Growing Preference For Injectable And Targeted Drug Delivery
  • 4.2.4 Expansion Of Online And Hospital Pharmacy Distribution Channels
  • 4.2.5 Development Of Supportive Therapies Such As Myostatin Inhibitors And Utrophin Modulators

5. Duchenne Muscular Dystrophy Drugs Market Analysis Of End Use Industries

• 5.1 Hospital Pharmacies
• 5.2 Retail Pharmacies
• 5.3 Online Pharmacies
• 5.4 Specialty Clinics
• 5.5 Research Institutions

6. Duchenne Muscular Dystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Duchenne Muscular Dystrophy Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Duchenne Muscular Dystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Duchenne Muscular Dystrophy Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Duchenne Muscular Dystrophy Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Duchenne Muscular Dystrophy Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Duchenne Muscular Dystrophy Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Duchenne Muscular Dystrophy Drugs Market Segmentation

• 9.1. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
• 9.2. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.3. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.4. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
• 9.5. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prednisone, Deflazacort, Other Corticosteroids
• 9.6. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies
• 9.7. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies

10. Duchenne Muscular Dystrophy Drugs Market Regional And Country Analysis

• 10.1. Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

• 11.1. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Duchenne Muscular Dystrophy Drugs Market

• 12.1. China Duchenne Muscular Dystrophy Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Duchenne Muscular Dystrophy Drugs Market

• 13.1. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Duchenne Muscular Dystrophy Drugs Market

• 14.1. Japan Duchenne Muscular Dystrophy Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Duchenne Muscular Dystrophy Drugs Market

• 15.1. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Duchenne Muscular Dystrophy Drugs Market

• 16.1. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Duchenne Muscular Dystrophy Drugs Market

• 17.1. South Korea Duchenne Muscular Dystrophy Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Duchenne Muscular Dystrophy Drugs Market

• 18.1. Taiwan Duchenne Muscular Dystrophy Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Duchenne Muscular Dystrophy Drugs Market

• 19.1. South East Asia Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Duchenne Muscular Dystrophy Drugs Market

• 20.1. Western Europe Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Duchenne Muscular Dystrophy Drugs Market

• 21.1. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Duchenne Muscular Dystrophy Drugs Market

• 22.1. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Duchenne Muscular Dystrophy Drugs Market

• 23.1. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Duchenne Muscular Dystrophy Drugs Market

• 24.1. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Duchenne Muscular Dystrophy Drugs Market

• 25.1. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Duchenne Muscular Dystrophy Drugs Market

• 26.1. Eastern Europe Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Duchenne Muscular Dystrophy Drugs Market

• 27.1. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Duchenne Muscular Dystrophy Drugs Market

• 28.1. North America Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Duchenne Muscular Dystrophy Drugs Market

• 29.1. USA Duchenne Muscular Dystrophy Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Duchenne Muscular Dystrophy Drugs Market

• 30.1. Canada Duchenne Muscular Dystrophy Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Duchenne Muscular Dystrophy Drugs Market

• 31.1. South America Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Duchenne Muscular Dystrophy Drugs Market

• 32.1. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Duchenne Muscular Dystrophy Drugs Market

• 33.1. Middle East Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Duchenne Muscular Dystrophy Drugs Market

• 34.1. Africa Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Duchenne Muscular Dystrophy Drugs Market Regulatory and Investment Landscape

36. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Company Profiles

• 36.1. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Duchenne Muscular Dystrophy Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Duchenne Muscular Dystrophy Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Italfarmaco S.p.A Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sarepta Therapeutics Inc Overview, Products and Services, Strategy and Financial Analysis

37. Duchenne Muscular Dystrophy Drugs Market Other Major And Innovative Companies

• PTC Therapeutics Inc, FibroGen Inc, Wave Life Sciences Ltd, Solid Biosciences Inc, NS Pharma, Capricor Therapeutics Inc, Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc, EspeRare Foundation, Cure Rare Disease, Akashi Therapeutics Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Co Ltd

38. Global Duchenne Muscular Dystrophy Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Drugs Market

40. Duchenne Muscular Dystrophy Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Duchenne Muscular Dystrophy Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Duchenne Muscular Dystrophy Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Duchenne Muscular Dystrophy Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer